ImmunityBio

ImmunityBio is a life sciences company that focuses on immunotherapy.[1]

History

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[1][2]

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund trials involving non-human primates.[3] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[3]

Clinical Trails

Phase I/II

ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa[4]

Covid-19 Vaccine

The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a COVID‑19 vaccine developed by the United States-based ImmunityBio.[5][6]

The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa[7]

ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.[8][9]

References
  1. "NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter". BioSpace.com. 14 April 2020.
  2. Cross, Ryan (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
  3. Cohen, Jon (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
  4. "Covid-19 to Serve as Platform for South African Vaccine Industry". Bloomberg.com. 2021-03-19. Retrieved 2021-03-20.
  5. "SA's Biovac to team up with US based ImmunityBio in making its vaccine". BusinessInsider. Retrieved 2021-03-23.
  6. "ImmunityBio Inc: hAd5-Covid-19 – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 2021-03-23.
  7. "Covid-19 to Serve as Platform for South African Vaccine Industry". Bloomberg.com. 2021-03-19. Retrieved 2021-03-20.
  8. Fisher, Shamiela. "Nzimande excited about vaccine partnership between Biovac & ImmunityBio". ewn.co.za. Retrieved 2021-03-20.
  9. Sguazzin, Antony. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 2021-03-20.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.